Retro announces initial close of new financing at a $1.8B pre-money valuation, led by 4P Capital

Retro Biosciences

Retro announced the initial close of a funding round at a $1.8B pre-money valuation led by 4P Capital. RTR242, an oral drug meant to restart autophagy, went from indication selection to first-in-human dosing in 15 months.

• RTR242 progressed from indication selection to first-in-human Phase 1 in 15 months, remarkably fast for an oral autophagy activator.
• Parallel programs include cell therapy, tissue reprogramming, AI-enabled protein engineering and iPSC-derived blood disorder therapies.
• In-house cGMP manufacturing facility supports cell therapy programs; additional first-in-human milestones planned for 2026-2027.